Physiology of the renal interstitium

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 10, 2015, Pages 1831-1840

  Zeisberg, Michael ^a   Kalluri, Raghu ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; EPO; ERYTHROPOIETIN; GLYCOPROTEIN; RENIN; UNCLASSIFIED DRUG; EPO PROTEIN, HUMAN;

ARTICLE; CELL HETEROGENEITY; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DISEASE SEVERITY; ENDOCRINE FUNCTION; FIBROBLAST; HUMAN; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; PATHOPHYSIOLOGY; PROTEIN FUNCTION; ANEMIA; ANIMAL; BIOSYNTHESIS; CYTOLOGY; EMBRYOLOGY; KIDNEY; KIDNEY DISEASE; MESENCHYMAL STROMA CELL; METABOLISM; NEURAL CREST; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECRETION (PROCESS); ULTRASTRUCTURE;

ADENOSINE; ANEMIA; ANIMALS; ERYTHROPOIETIN; FIBROBLASTS; HUMANS; KIDNEY; KIDNEY DISEASES; MESENCHYMAL STROMAL CELLS; NEURAL CREST; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84943334128     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00640114     Document Type: Article

References (107)

1. Lemley KV, KrizW: Anatomyof the renal interstitium. Kidney Int 39: 370-381, 1991
2. Kaissling B, Le Hir M: The renal cortical interstitium: Morphological and functional aspects. Histochem Cell Biol 130: 247- 262, 2008
3. Kuncio GS, Neilson EG, Haverty T: Mechanisms of tubulointerstitial fibrosis. Kidney Int 39: 550-556, 1991
4. Zeisberg M, Neilson EG: Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 21: 1819-1834, 2010
5. Eddy AA: Molecular insights into renal interstitial fibrosis [editorial]. J Am Soc Nephrol 7: 2495-2508, 1996
6. Kriz W, Napiwotzky P: Structural and functional aspects of the renal interstitium. Contrib Nephrol 16: 104-108, 1979
7. Knepper MA, Danielson RA, Saidel GM, Post RS: Quantitative analysis of renal medullary anatomy in rats and rabbits. Kidney Int 12: 313-323, 1977
8. Takahashi-Iwanaga H: The three-dimensional cytoarchitecture of the interstitial tissue in the rat kidney. Cell Tissue Res 264: 269-281, 1991
9. Teteris SA, Engel DR, Kurts C: Homeostatic and pathogenic role of renal dendritic cells. Kidney Int 80: 139-145, 2011
10. Nelson PJ, Rees AJ, GriffinMD, Hughes J, Kurts C,Duffield J: The renal mononuclear phagocytic system. J Am Soc Nephrol 23: 194-203, 2012
11. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 6: 392-401, 2006
12. Zeisberg M, Strutz F, Müller GA: Role of fibroblast activation in inducing interstitial fibrosis. JNephrol 13[Suppl 3]: S111-S120, 2000
13. Enge M, Bjarnegård M, Gerhardt H, Gustafsson E, Kalén M, Asker N, Hammes HP, Shani M, Fässler R, Betsholtz C: Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J 21: 4307-4316, 2002
14. Abramsson A, Lindblom P, Betsholtz C: Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112: 1142-1151, 2003
15. Kurtz A: Renin release: Sites, mechanisms, and control. Annu Rev Physiol 73: 377-399, 2011
16. Kurtz A, Eckardt KU, Neumann R, Kaissling B, Le Hir M, Bauer C: Site of erythropoietin formation. Contrib Nephrol 76: 14-20, discussion 21-23, 1989
17. Komuro T: Re-evaluation of fibroblasts and fibroblast-like cells. Anat Embryol (Berl) 182: 103-112, 1990
18. Franke WW, Schmid E, Osborn M, Weber K: Different intermediate-sized filaments distinguished by immunofluorescence microscopy. Proc Natl Acad Sci U S A 75: 5034-5038, 1978
19. Lazarides E, Balzer DR Jr: Specificity of desmin to avian and mammalian muscle cells. Cell 14: 429-438, 1978
20. Tuszynski GP, Frank ED, Damsky CH, Buck CA, Warren L: The detection of smooth muscle desmin-like protein in BHK21/C13 fibroblasts. J Biol Chem 254: 6138-6143, 1979
21. Gardner H, Kreidberg J, Koteliansky V, Jaenisch R: Deletion of integrin alpha 1 by homologous recombination permits normal murine development but gives rise to a specific deficit in cell adhesion. Dev Biol 175: 301-313, 1996
22. Vogel W, Gish GD, Alves F, Pawson T: The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell 1: 13-23, 1997
23. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG: Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 130: 393-405, 1995
24. Marxer-Meier A, Hegyi I, Loffing J, Kaissling B: Postnatal maturation of renal cortical peritubular fibroblasts in the rat. Anat Embryol (Berl) 197: 143-153, 1998
25. Thompson LF, Ruedi JM, Glass A, LowMG, Lucas AH: Antibodies to 59-nucleotidase (CD73), a glycosyl-phosphatidylinositolanchored protein, cause human peripheral blood T cells to proliferate. J Immunol 143: 1815-1821, 1989
26. Fellström B, Klareskog L, Heldin CH, Larsson E, Rönnstrand L, Terracio L, Tufveson G, Wahlberg J, Rubin K: Platelet-derived growth factor receptors in the kidney-upregulated expression in inflammation. Kidney Int 36: 1099-1102, 1989
27. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS: Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 176: 85-97, 2010
28. Gabbiani G, Kapanci Y, Barazzone P, Franke WW: Immunochemical identification of intermediate-sized filaments in human neoplastic cells. A diagnostic aid for the surgical pathologist. Am J Pathol 104: 206-216, 1981
29. LeBleu VS, Taduri G, O'Connell J, Teng Y, Cooke VG,Woda C, Sugimoto H, Kalluri R: Origin and function of myofibroblasts in kidney fibrosis. Nat Med 19: 1047-1053, 2013
30. Lacombe C, Mayeux P: Biology of erythropoietin. Haematologica 83: 724-732, 1998
31. Jelkmann W: Physiology and pharmacology of erythropoietin. Transfus Med Hemother 40: 302-309, 2013
32. FriedW, Kilbridge T, Krantz S,McDonald TP, Lange RD: Studies on extrarenal erythropoietin. J Lab Clin Med 73: 244-248, 1969
33. Cahan C, Hoekje PL, Goldwasser E, Decker MJ, Strohl KP: Assessing the characteristic between length of hypoxic exposure and serum erythropoietin levels. Am J Physiol 258: R1016- R1021, 1990
34. Nangaku M, Eckardt KU: Hypoxia and the HIF systemin kidney disease. J Mol Med (Berl) 85: 1325-1330, 2007
35. Weidemann A, Johnson RS: Nonrenal regulation of EPO synthesis. Kidney Int 75: 682-688, 2009
36. Chiang CK, Nangaku M, Tanaka T, Iwawaki T, Inagi R: Endoplasmic reticulum stress signal impairs erythropoietin production: a role for ATF4. Am J Physiol Cell Physiol 304: C342-C353, 2013
37. Miescher F: Über die Beziehungen zwischen Meereshöhe und Beschaffenheit des Blutes. Korrespbl Schweiz Arz 23: 809-830, 1893
38. Erslev A: Humoral regulation of red cell production. Blood 8: 349-357, 1953
39. Wojchowski D: Eugene Goldwasser (1922-2010). Nature 470: 40, 2011
40. Eckardt KU, Koury ST, Tan CC, Schuster SJ, Kaissling B, Ratcliffe PJ, Kurtz A: Distribution of erythropoietin producing cells in rat kidneys during hypoxic hypoxia. Kidney Int 43: 815-823, 1993
41. Pan X, Suzuki N, Hirano I, Yamazaki S, Minegishi N, Yamamoto M: Isolation and characterization of renal erythropoietinproducing cells from genetically produced anemia mice. PLoS ONE 6: e25839, 2011
42. Maxwell AP, Lappin TR, Johnston CF, Bridges JM, McGeown MG: Erythropoietin production in kidney tubular cells. Br J Haematol 74: 535-539, 1990
43. Unger EF, Thompson AM, Blank MJ, Temple R: Erythropoiesisstimulating agents-time for a reevaluation. N Engl J Med 362: 189-192, 2010
44. Macdougall IC: Optimizing the use of erythropoietic agents- pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 17[Suppl 5]: 66-70, 2002
45. Pagel H, Jelkmann W, Weiss C: O2-supply to the kidneys and the production of erythropoietin. Respir Physiol 77: 111-117, 1989
46. JelkmannW: Regulation of erythropoietin production. J Physiol 589: 1251-1258, 2011
47. Singh AK: Anemia of chronic kidney disease. Clin J Am Soc Nephrol 3: 3-6, 2008
48. Dewi FR, Fatchiyah F: Methylation impact analysis of erythropoietin (EPO) gene to hypoxia inducible factor-1a (HIF-1a) activity. Bioinformation 9: 782-787, 2013
49. Asada N, Takase M, Nakamura J, Oguchi A, AsadaM, SuzukiN, Yamamura K, Nagoshi N, Shibata S, Rao TN, Fehling HJ, Fukatsu A, Minegishi N, Kita T, Kimura T, Okano H, Yamamoto M, Yanagita M: Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 121: 3981-3990, 2011
50. Souma T, Yamazaki S, Moriguchi T, Suzuki N, Hirano I, Pan X, Minegishi N, AbeM, KiyomotoH, Ito S, Yamamoto M: Plasticity of renal erythropoietin-producing cells governs fibrosis. J Am Soc Nephrol 24: 1599-1616, 2013
51. BernhardtWM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Günzler V, Eckardt KU: Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21: 2151-2156, 2010
52. Artunc F, Risler T: Serum erythropoietin concentrations and responses to anaemia in patients with orwithout chronic kidney disease. Nephrol Dial Transplant 22: 2900-2908, 2007
53. Mercadal L, Metzger M, Casadevall N, Haymann JP, Karras A, Boffa JJ, Flamant M, Vrtovsnik F, Stengel B, Froissart M, NephroTest Study Group: Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol 7: 35-42, 2012 54. Chandra M, Clemons GK, McVicar MI: Relation of serum erythropoietin levels to renal excretory function: Evidence for lowered set point for erythropoietin production in chronic renal failure. J Pediatr 113: 1015-1021, 1988
54. Thomas M, Tsalamandris C, MacIsaac R, Jerums G: Anaemia in diabetes: An emerging complication of microvascular disease. Curr Diabetes Rev 1: 107-126, 2005
55. de Klerk G, Wilmink JM, Rosengarten PC, Vet RJ, Goudsmit R: Serum erythropoietin (ESF) titers in anemia of chronic renal failure. J Lab Clin Med 100: 720-734, 1982
56. Eckardt KU, Möllmann M, Neumann R, Brunkhorst R, Burger HU, Lonnemann G, Scholz H, Keusch G, Buchholz B, Frei U: Erythropoietin in polycystic kidneys. J Clin Invest 84: 1160- 1166, 1989
57. Inomata S, ItohM, ImaiH, Sato T: Serum levels of erythropoietin as a novel marker reflecting the severity of diabetic nephropathy. Nephron 75: 426-430, 1997
58. Bosman DR, Osborne CA,Marsden JT,Macdougall IC, Gardner WN,Watkins PJ: Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure. Diabet Med 19: 65-69, 2002
59. Naeshiro I, Sato K, Chatani F, Sato S: Possible mechanismfor the anemia induced by candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, in rats. Eur J Pharmacol 354: 179- 187, 1998
60. Ertürk S, Atesx K, Duman N, Karatan O, Erbay B, Ertu_g E: Unresponsiveness to recombinant human erythropoietin in haemodialysis patients: Possible implications of angiotensinconverting enzyme inhibitors. Nephrol Dial Transplant 11: 396-397, 1996
61. Franke K, Gassmann M, Wielockx B: Erythrocytosis: The HIF pathway in control. Blood 122: 1122-1128, 2013
62. Le Hir M, Kaissling B: Distribution and regulation of renal ecto-59-nucleotidase: Implications for physiological functions of adenosine. Am J Physiol 264: F377-F387, 1993
63. Nishiyama A, Rahman M, Inscho EW: Role of interstitial ATP and adenosine in the regulation of renal hemodynamics and microvascular function. Hypertens Res 27: 791-804, 2004
64. Li L,MizelD, Huang Y, Eisner C, Hoerl M, ThielM, Schnermann J: Tubuloglomerular feedback and renal function in mice with targeted deletion of the type 1 equilibrative nucleoside transporter. Am J Physiol Renal Physiol 304: F382-F389, 2013
65. Vallon V, Mühlbauer B, Osswald H: Adenosine and kidney function. Physiol Rev 86: 901-940, 2006
66. Ozüyaman B, Ding Z, Buchheiser A, Koszalka P, Braun N, Gödecke A, Decking UK, Zimmermann H, Schrader J: Adenosine produced via the CD73/ecto-59-nucleotidase pathway has no impact on erythropoietin production but is associated with reduced kidney weight. Pflugers Arch 452: 324-331, 2006
67. KoboriH,NangakuM,Navar LG, NishiyamaA: The intrarenal reninangiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59: 251-287, 2007
68. Baylis C, Engels K, Hymel A, Navar LG: Plasma renin activity and metabolic clearance rate of angiotensin II in the unstressed aging rat. Mech Ageing Dev 97: 163-172, 1997
69. Sequeira Lopez ML, Pentz ES, Robert B, Abrahamson DR, Gomez RA: Embryonic origin and lineage of juxtaglomerular cells. Am J Physiol Renal Physiol 281: F345-F356, 2001
70. Castrop H, Höcherl K, Kurtz A, Schweda F, Todorov V, Wagner C: Physiology of kidney renin. Physiol Rev 90: 607-673, 2010
71. Skøtt O, Briggs JP: Direct demonstration of macula densamediated renin secretion. Science 237: 1618-1620, 1987
72. Hackenthal E, Paul M, Ganten D, Taugner R: Morphology, physiology, and molecular biology of renin secretion. Physiol Rev 70: 1067-1116, 1990
73. Kim SM, Chen L, Faulhaber-Walter R, OppermannM, Huang Y, Mizel D, Briggs JP, Schnermann J: Regulation of renin secretion and expression inmice deficient in beta1- and beta2-adrenergic receptors. Hypertension 50: 103-109, 2007
74. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators: A controlled trial of renal denervation for resistant hypertension.NEngl J Med 370: 1393- 1401, 2014
75. Fisher JP, Paton JF: The sympathetic nervous system and blood pressure in humans: Implications for hypertension. J Hum Hypertens 26: 463-475, 2012
76. Davidson AC, Bisognano JD: Interventional approaches for resistant hypertension. Curr Opin Nephrol Hypertens 21: 475- 480, 2012
77. Zeisberg M, Müller GA: Mechanistic insights into the antifibrotic activity of aliskiren in the kidney. Hypertens Res 35: 266-268, 2012
78. Sequeira López ML, Pentz ES, Nomasa T, Smithies O, Gomez RA: Renin cells are precursors formultiple cell types that switch to the renin phenotype when homeostasis is threatened. Dev Cell 6: 719-728, 2004
79. Ayan S, Roth JA, Freeman MR, Bride SH, Peters CA: Partial ureteral obstruction dysregulates the renal renin-angiotensin system in the fetal sheep kidney. Urology 58: 301-306, 2001
80. Mimura I, Nangaku M: The suffocating kidney: Tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol 6: 667-678, 2010
81. Sealey JE, Alderman MH, Furberg CD, Laragh JH: Reninangiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels. Am J Hypertens 26: 727-738, 2013
82. Huby AC, Kavvadas P, Alfieri C, Abed A, Toubas J, Rastaldi MP, Dussaule JC, Chatziantoniou C, Chadjichristos CE: The RenTg mice: A powerful tool to study renin-dependent chronic kidney disease. PLoS ONE 7: e52362, 2012
83. Tarazi RC, Frohlich ED, Dustan HP, Gifford RW Jr, Page IH: Hypertension and high hematocrit. Another clue to renal arterial disease. Am J Cardiol 18: 855-858, 1966
84. Vlahakos DV, Marathias KP, Madias NE: The role of the reninangiotensin system in the regulation of erythropoiesis. Am J Kidney Dis 56: 558-565, 2010
85. Kuriyama S, TomonariH, Tokudome G,HoriguchiM, HayashiH, Kobayashi H, Ishikawa M, Hosoya T: Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res 25: 849-855, 2002
86. Jacobsen P, Andersen S, Jensen BR, Parving HH: Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 14: 992-999, 2003
87. Vlahakos DV, Marathias KP, Agroyannis B, Madias NE: Posttransplant erythrocytosis. Kidney Int 63: 1187-1194, 2003
88. Ertürk S, Nergizoglu G, Atesx K, Duman N, Erbay B, Karatan O, Ertu_g AE: The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients. Nephrol Dial Transplant 14: 1912- 1916, 1999
89. Volpe M, Tritto C, Testa U, Rao MA, Martucci R, Mirante A, Enea I, Russo R, Rubattu S, Condorelli GL, Cangianiello S, Trimarco B, Peschle C, Condorelli M: Blood levels of erythropoietin in congestive heart failure and correlationwith clinical, hemodynamic, and hormonal profiles. Am J Cardiol 74: 468-473, 1994
90. Eckardt KU: Cardiovascular consequences of renal anaemia and erythropoietin therapy. Nephrol Dial Transplant 14: 1317- 1323, 1999
91. Rosario R, Epstein M: Relationship between erythropoietin administration and alterations of renin-angiotensin-aldosterone. J Renin Angiotensin Aldosterone Syst 7: 135-138, 2006
92. Yamauchi Y, Abe K, Mantani A, Hitoshi Y, Suzuki M, Osuzu F, Kuratani S, Yamamura K: A novel transgenic technique that allows specific marking of the neural crest cell lineage in mice. Dev Biol 212: 191-203, 1999
93. Luche H, Weber O, Nageswara Rao T, Blum C, Fehling HJ: Faithful activation of an extra-bright red fluorescent protein in "knock-in" Cre-reporter mice ideally suited for lineage tracing studies. Eur J Immunol 37: 43-53, 2007
94. Obara N, Suzuki N, KimK, Nagasawa T, Imagawa S, Yamamoto M: Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 111: 5223-5232, 2008
95. Kim HS,Maeda N, Oh GT, Fernandez LG, Gomez RA, Smithies O: Homeostasis in mice with genetically decreased angiotensinogen is primarily by an increased number of reninproducing cells. J Biol Chem 274: 14210-14217, 1999
96. Sequeira Lopez ML, Gomez RA: Development of the renal arterioles. J Am Soc Nephrol 22: 2156-2165, 2011
97. Karger C, Kurtz F, Steppan D, Schwarzensteiner I, Machura K, Angel P, Banas B, Risteli J, Kurtz A: Procollagen I-expressing renin cell precursors. Am J Physiol Renal Physiol 305: F355-F361, 2013
98. Kurt B, Paliege A, Willam C, Schwarzensteiner I, Schucht K, Neymeyer H, Sequeira-Lopez ML, Bachmann S, Gomez RA, Eckardt KU, Kurtz A: Deletion of von Hippel-Lindau protein converts renin-producing cells into erythropoietin-producing cells. J Am Soc Nephrol 24: 433-444, 2013
99. Bohle A, Bader R, Grund KE, Mackensen S, Neunhoeffer J: Serum creatinine concentration and renal interstitial volume. Analysis of correlations in endocapillary (acute) glomerulonephritis and in moderately severe mesangioproliferative glomerulonephritis. Virchows Arch A Pathol Anat Histol 375: 87-96, 1977
100. Bohle A, Christ H, Grund KE, Mackensen S: The role of the interstitium of the renal cortex in renal disease. Contrib Nephrol 16: 109-114, 1979
101. Risdon RA, Sloper JC, De Wardener HE: Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 2: 363-366, 1968
102. Cohen EP: Fibrosis causes progressive kidney failure. Med Hypotheses 45: 459-462, 1995
103. Cohen EP, Regner K, Fish BL, Moulder JE: Stenotic glomerulotubular necks in radiation nephropathy. J Pathol 190: 484-488, 2000
104. Becker GJ, Hewitson TD: The role of tubulointerstitial injury in chronic renal failure. Curr Opin Nephrol Hypertens 9: 133-138, 2000
105. Zeisberg M, Kalluri R: Cellular mechanisms of tissue fibrosis. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol 304: C216-C225, 2013
106. Eddy AA: Progression in chronic kidney disease. Adv Chronic Kidney Dis 12: 353-365, 2005
107. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998